Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12002951 | 0.85 | HRH3 (0.44) | HRH3MAPK1JAK2JAK1MEN1 | |
| SCHEMBL20918704 | 0.82 | HRH3 (0.42) | HRH3MAPK1JAK2JAK1MEN1 | |
| SCHEMBL31334788 | 0.82 | MAPK1 (0.36) | HRH3MAPK1MEN1KMT2A | |
| SCHEMBL2633813 | 0.82 | HRH3 (0.42) | HRH3MAPK1JAK2JAK1MEN1 | |
| SCHEMBL2223446 | 0.81 | HRH3 (0.41) | HRH3MAPK1MEN1ALDH1A1KMT2A | |
| SCHEMBL3163753 | 0.81 | HRH3 (0.41) | HRH3MAPK1JAK2JAK1MEN1 | |
| SCHEMBL26127504 | 0.80 | CHRNB2 (0.47) | ALDH1A1 | |
| SCHEMBL30686990 | 0.79 | HRH3 (0.40) | HRH3MAPK1JAK2JAK1MEN1 | |
| SCHEMBL20512435 | 0.79 | MAPK1 (0.34) | HRH3MAPK1MEN1KMT2A | |
| SCHEMBL25341759 | 0.79 | HRH3 (0.35) | HRH3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885MAPK1 2017/4885JAK2 184/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HRH3 3631/4885MAPK1 2017/4885JAK2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.